Many Firsts As Celltrion/Pfizer's Inflectra Becomes Second US Biosimilar
This article was originally published in SRA
Executive Summary
Move over Zarxio. There's a new kid in town: Inflectra (infliximab-dyyb) has received approval from the US Food and Drug Administration as the first monoclonal antibody biosimilar licensed in the US1.